
DexCom (DXCM) Stock Forecast & Price Target
DexCom (DXCM) Analyst Ratings
Bulls say
DexCom is experiencing consistent organic growth and has exceeded expectations in both US sales and international sales, indicating strong market demand. The company is also evolving its product to provide integration with insulin pumps, which could drive further growth and establish a strong competitive moat. Despite facing potential risks such as regulatory hurdles and competition, DexCom has demonstrated strong margins and consistent FCF performance, making it a favorable investment opportunity in the diabetes device industry.
Bears say
DexCom is facing multiple challenges, including regulatory delays impacting future revenues and a potentially smaller market opportunity than projected, potentially limiting their revenue growth potential. These challenges, combined with some slight multiple compression since the last valuation update, warrant a negative outlook on the stock. Additionally, while management has reiterated all previously provided guidance metrics, there is uncertainty surrounding regulatory requirements at the FDA, which could impact the company's ability to meet its projected revenue and earnings growth goals. Overall, there is likely limited upside potential for DexCom in the near future, leading to a negative outlook on the stock.
This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.
DexCom (DXCM) Analyst Forecast & Price Prediction
Start investing in DexCom (DXCM)
Order type
Buy in
Order amount
Est. shares
0 shares